Chinese Clinical Oncology ›› 2018, Vol. 23 ›› Issue (5): 419-423.

Previous Articles     Next Articles

Expression of DCLK1 and Bmi-1 in colorectal cancer and their clinical significance

  

  1. Department of Gastroenterology, Affiliated Hospital of Yan’an University, Yan’an 716000, China
  • Received:2017-11-25 Revised:2018-02-09 Online:2018-05-31 Published:2018-06-07

Abstract: Objective  To investigate the expression of doublecortin-like kinase 1 (DCLK1) and B-cell specific moloney leukemia virus insertion site 1(Bmi-1) in colorectal cancer and their clinical significance. Methods  The expression of DCLK1 and Bmi-1 were detected in the 74 cases of colorectal cancer and the corresponding adjacent normal tissues by Max Vision method. The correlation between the expression of two protein and their relationship with clinical pathological parameters of colorectal cancer were analyzed. Results   The positive expression rates of DCLK1 and Bmi-1 in colorectal cancer were 68.9% and 62.2%, higher than 27.0% and 23.0% in their adjacent normal tissues respectively, and the differences were significant (P<0.05). DCLK1 was significantly correlated with infiltration’s depth, lymphatic metastasis and Dukes’ stage in colorectal cancer(P<0.05). Bmi-1 was signifcantly correlated with tumor classification, infiltration’s depth, lymphatic metastasis and Dukes’ stage(P<0.05). The expression of DCLK1 was positively correlated with that of Bmi-1 (r=0.259, P=0.026). Conclusion   DCLK1 and Bmi-1 were highly expressed in colorectal cancer tissues and associated with the development and progression of colorectal cancer. The joint detection of them may provide a new approach for the clinical diagnosis, treatment and prognostic evaluation of colorectal cancer.

Key words: Colorectal cancer, Doublecortin-like kinase 1 (DCLK1), B-cell specific moloney leukemia virus insertion site 1(Bmi-1), Immunohistochemistry

CLC Number: 

  • R735.3
[1] ZHANG Dezhi, ZHANG Yu, ZHU Shaogong.. Effect of rs10013228 polymorphism of VEGFR2 gene on prognosis of patients with R0 resection of colorectal cancer [J]. Chinese Clinical Oncology, 2018, 23(5): 424-428.
[2] YANG Yefan, MA Zhonghua, WANG Keming.. Progression of long chain non coding RNA in the regulation of drug resistance in colorectal cancer [J]. Chinese Clinical Oncology, 2018, 23(5): 458-462.
[3] WANG Shanshan, WANG Haiyan, WU Bin, ZHAO Lihong, LI Dong, XIE Yan. . Observation of apatinib mesylate treatment on colon cancer failed in multi-line chemotherapy [J]. Chinese Clinical Oncology, 2018, 23(5): 453-457.
[4] YAO Bo, LU Na.. The role of radiotherapy in the management of rectal cancer with synchronous metastases [J]. Chinese Clinical Oncology, 2018, 23(5): 463-466.
[5] . Progression of monocolonal antibodies for colorectal cancer in 2008 [J]. Chinese Clinical Oncology, 2009, 14(1): 1-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Chinese Clinical Oncology, 2009, 14(1): 96 .
[2] . [J]. Chinese Clinical Oncology, 2009, 14(1): 89 .
[3] . [J]. Chinese Clinical Oncology, 2009, 14(1): 80 .
[4] . [J]. Chinese Clinical Oncology, 2009, 14(1): 74 .
[5] . [J]. Chinese Clinical Oncology, 2009, 14(1): 47 .
[6] . [J]. Chinese Clinical Oncology, 2009, 14(1): 68 .
[7] XUWei-guo,YANGXiao-qing,HAOShi-zhu,SONGJi-ning,ZHANGPeng-dong,HUChan-chan,WANGWen-ya. Theexpressionofneuropilin-1anditscorrelationwithangiogenesisincolorectalcance[J]. Chinese Clinical Oncology, 2009, 14(1): 29 .
[8] . [J]. Chinese Clinical Oncology, 2009, 14(1): 70 .
[9] . [J]. Chinese Clinical Oncology, 2009, 14(1): 43 .
[10] . [J]. Chinese Clinical Oncology, 2009, 14(1): 51 .